Bayer Aktiengesellschaft (OTCMKTS:BAYRY) has earned an average rating of “Buy” from the thirteen ratings firms that are covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $39.00.
BAYRY has been the topic of a number of research reports. Berenberg Bank cut their price target on Bayer Aktiengesellschaft from €74.00 ($84.09) to €60.00 ($68.18) and set a “buy” rating on the stock in a report on Monday, August 9th. Morgan Stanley reaffirmed an “overweight” rating on shares of Bayer Aktiengesellschaft in a research report on Wednesday, November 10th. Credit Suisse Group reiterated a “neutral” rating on shares of Bayer Aktiengesellschaft in a report on Wednesday, November 10th. JPMorgan Chase & Co. restated an “overweight” rating on shares of Bayer Aktiengesellschaft in a report on Wednesday, November 10th. Finally, AlphaValue upgraded shares of Bayer Aktiengesellschaft to a “buy” rating in a research note on Monday, November 15th.
OTCMKTS BAYRY traded down $0.40 on Thursday, reaching $13.39. The company had a trading volume of 617,463 shares, compared to its average volume of 457,803. The company’s fifty day moving average is $13.97 and its 200-day moving average is $14.74. The firm has a market capitalization of $52.60 billion, a price-to-earnings ratio of 267.75, a price-to-earnings-growth ratio of 2.01 and a beta of 1.23. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.80 and a current ratio of 1.16. Bayer Aktiengesellschaft has a 1-year low of $13.10 and a 1-year high of $17.34.
Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment engages in the development, production and marketing of prescription products for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology and ophthalmology; diagnostic imaging equipment and the necessary contrast agents.
Featured Story: News Sentiment
Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.